Life Sciences

  • December 12, 2017

    Jury Sides With SEC, Finds Syringe Maker Juiced Stock

    A Georgia federal jury on Monday sided with the U.S. Securities and Exchange Commission and found that medical device maker Revolutions Medical Corp. and its top executive issued false statements to pump up its stock price.

  • December 12, 2017

    State AGs Fight To Block Trump's Birth Control Rules

    Five state attorneys general urged a California federal judge at a hearing Tuesday to block the Trump administration’s proposed rules limiting access to birth control, arguing the rules violate the Affordable Care Act and will allow employers to unconstitutionally deny millions of women coverage for contraceptives by invoking religious beliefs.

  • December 12, 2017

    Biopharm Ex-CEO Used Travel Funds For Hooters, SEC Says

    The U.S. Securities and Exchange Commission on Tuesday sued the former CEO of a Tennessee biopharmaceutical firm, alleging that he paid for personal expenses like big tips at Hooters and breast enhancement surgery for female friends with $3.2 million he got from his company by submitting bogus cash advance and reimbursement requests for business-related travel.

  • December 12, 2017

    Ill. Doctor Gets 14 Mos. For Illegal Drug Distribution

    An Illinois doctor who pled guilty last year to several counts of illegally distributing hydrocodone was sentenced Monday to 14 months in prison.

  • December 12, 2017

    Calif. Surrogacy Agency Not Covered For Negligence Suit

    Admiral Insurance Co. need not defend a surrogacy agency in a negligence suit brought by former clients whose surrogate-born daughter developed a rare form of eye cancer, as the agency failed to disclose the claim on its policy application, according to a California appellate opinion filed Tuesday.

  • December 12, 2017

    GOP Introduces 5 Bills To Delay Affordable Care Act Taxes

    House Republicans introduced five bills on Tuesday aimed at undercutting the employer mandate and taxes imposed under the Affordable Care Act, looking to reduce the tax burden stemming from the health care law in 2018.

  • December 12, 2017

    Amgen Whistleblower Was Original Source, 2nd Circ. Told

    An attorney for a whistleblower told the Second Circuit Tuesday that his client was an “original source” under the False Claims Act, because he showed Amgen Inc. knew it falsely promoted quality of life benefits for its anemia biologic Epogen.

  • December 12, 2017

    Retailers Settle Claims Against Teikoku In Lidoderm MDL

    A handful of retailers, including Walgreen Co., Rite Aid Corp., CVS Pharmacy Inc. and Kroger Co., told a California federal court Tuesday that they have settled claims against Japanese pharmaceutical company Teikoku and a domestic subsidiary in antitrust multidistrict litigation over the Lidoderm pain patch.

  • December 12, 2017

    Split Del. Justices OK Denial Of $50M Drug Approval Bonus

    Delaware's Supreme Court narrowly upheld Tuesday a lower court decision that denied stockholders of the former Calistoga Pharmaceuticals a $50 million bonus payment for limited European Union approval of a new drug for one form of blood cancer.

  • December 12, 2017

    Pharma Cos. Settle Pa. Skelaxin Pay-For-Delay Fight

    Generics maker SigmaPharm Inc. has settled a Pennsylvania state lawsuit accusing Mutual Pharmaceutical Co. Inc. of conspiring with Pfizer unit King Pharmaceuticals Inc. to suppress the release of generic forms of the muscle relaxant Skelaxin, according to an order docketed Tuesday.

  • December 12, 2017

    Fed. Circ. Affirms PTAB Ax Of Daiichi’s Heart Drug Patents

    The Federal Circuit upheld on Tuesday a Patent Trial and Appeal Board decision that invalidated as obvious a pair of Daiichi Sankyo’s patents for use in the anti-blood clot drug Effient, which have been asserted in numerous lawsuits.

  • December 12, 2017

    FDA Warning Wire: Chocolate 'Snuff' Sold As Street Drug Sub

    The U.S. Food and Drug Administration took a bite out of the marketers and distributors of a chocolate “snuff” for peddling the powder as an alternative to illegal street drugs and scolded a South Korean drugmaker for slipshod quality control practices. Here's this week’s roundup of the FDA’s enforcement activities.

  • December 12, 2017

    Actavis Asks Calif. Justices To Revive Opioid Coverage Bid

    Actavis asked California's high court late Monday to resurrect its effort to obtain coverage from Travelers for lawsuits alleging its misleading marketing of painkillers has fueled the nation's opioid addiction problem and caused a spike in heroin use, saying an appellate court's decision favoring the insurer bucked decades of precedent.

  • December 11, 2017

    Fed. Circ. Says It Can't Review PTAB Re-Exam Terminations

    The Federal Circuit on Monday said it does not have the power to review Patent and Trademark Appeal Board decisions to terminate patent re-examinations in a short order refusing to revive a challenge to an Illumina Inc. diagnostic patent.

  • December 11, 2017

    Surgeon Tells Jury Complications Not Limited To J&J Mesh

    The chief of female pelvic medicine at Hackensack University Medical Center told a New Jersey jury Monday that research and her own hundreds of surgeries reveal complications can arise from all methods of pelvic prolapse repair, not just Johnson & Johnson unit Ethicon’s Prolift, which a woman alleges is responsible for debilitating pain.

  • December 11, 2017

    Has Litigation Finance Shed Its Stigma?

    Once a taboo topic in the halls of BigLaw, litigation finance is winning over converts. And the peer pressure is building for rival law firms to join the bandwagon.

  • December 11, 2017

    Why Investors Are Taking The Leap To 3rd-Party Funding

    They often don’t know exactly what they’re buying, and there’s an ever-present chance they could come up empty in a given case. Here’s why investors are flocking to litigation finance anyway.

  • December 11, 2017

    What Your Colleagues Think Of Litigation Finance

    We asked, and you answered. Here are the results of Law360’s inaugural survey on third-party legal funding.

  • December 11, 2017

    Law Firm Doesn't Owe For GSK Contempt Order, 3rd Circ. Told

    The Mississippi law firm accused along with a fund administrator of erroneously distributing settlement money from multidistrict litigation against GlaxoSmithKline urged the Third Circuit on Monday to overturn a Pennsylvania district court’s order to indemnify the administrator, reasoning that the district court no longer had jurisdiction over GSK's already settled contempt allegations.

  • December 11, 2017

    Ex-Katten Atty's Expert Defends No-Work Consulting Deals

    An executive compensation expert on Monday told the jury in the fraud trial of former Katten Muchin Rosenman LLP attorney Evan Greebel that there’s nothing unusual about consulting deals that don’t involve much consulting, as the defense sought to refute a central theory of the government’s case.

Expert Analysis

  • Series

    40 Years Of FCPA: The Siemens Lesson — Tillerson Is Right

    solmssen.jpg

    Since its whopping $800 million Foreign Corrupt Practices Act settlement in 2008, Siemens cleaned up — and it has “cleaned up” in its long-standing competition with General Electric. How? As Secretary of State Rex Tillerson reportedly told President Donald Trump, you don’t need to pay bribes to succeed in international business, says Peter Y. Solmssen, former general counsel of Siemens.

  • Series

    40 Years Of FCPA: The Rise In International Enforcement

    Scarboro.jpg

    The 2008 Siemens matter — then the largest sanction ever imposed in a Foreign Corrupt Practices Act enforcement action — set the stage for future cross-collaboration in global anti-corruption enforcement, say Cheryl Scarboro, former chief of the FCPA Unit at the U.S. Securities and Exchange Commission, and Diana Wielocha of Simpson Thacher & Bartlett LLP.

  • Beware Marketing Cannabidiol Products: FDA Is Watching

    Brian Malkin

    The U.S. Food and Drug Administration recently issued warning letters concerning violations of the Federal Food, Drug and Cosmetic Act to four companies that market products containing cannabidiol, a nonpsychotropic cannabinoid found in cannabis. These letters should serve as a reminder that the FDA is watching closely, say attorneys with Arent Fox LLP.

  • Proactive Brand Protection Strategies For Pharma Innovators

    Laura Vogel

    Given the high cost of litigation and what's at stake in loss of market share to generic drug manufacturers, brand drug companies should employ a multipronged drug development and pre-litigation strategy, coming to market well prepared for battle, say Laura Vogel and Bella Satra of Barclay Damon LLP.

  • Series

    40 Years Of FCPA: Highlights From The 1st Corporate Trial

    Robert Feldman

    The Foreign Corrupt Practices Act case of U.S. v. Harris Corp. was tried in March 1991 — so long ago that pretty much only the parties and counsel remember it. With a smile, I’ve just about given up correcting people who say their case is "the only FCPA case ever to be tried,” says Robert Feldman of Quinn Emanuel Urquhart & Sullivan LLP.

  • Plavix Ruling Raises Learned Intermediary Questions

    Stefanie Colella-Walsh

    A federal judge in New Jersey recently granted summary judgment to drug manufacturers in a lawsuit alleging that Plavix caused gastrointestinal bleeding. The multidistrict litigation court, sitting in New Jersey, applied California's learned intermediary doctrine, but may not have reached the same conclusion had it applied New Jersey law, say Stefanie Colella-Walsh and Martin Schrama of Stark & Stark.

  • Series

    40 Years Of FCPA: The Strange Case That Started It All

    Burton Wiand

    At the U.S. Securities and Exchange Commission in April 1978, we filed a case against Page Airways and envisioned the trial of a precedent-setting enforcement action that would have defined Foreign Corrupt Practices Act standards at an early stage. Instead, the matter was settled under circumstances that I am sure are unique in SEC history, says Burton Wiand of Wiand Guerra King PA.

  • MDL Hearing Signals A New Phase For Opioid Suits

    Adam Fleischer

    On Nov. 30, the U.S. Judicial Panel on Multidistrict Litigation heard argument in over 100 government lawsuits seeking damages from pharmaceutical companies for the opioid epidemic. Whether these cases get consolidated and, if so, in which court, may have far-reaching implications, say Adam Fleischer and Kevin Harris of BatesCarey LLP.

  • The Billing Evolution: How Far Along Is Your Firm?

    Sharon Quaintance

    In a recent study, 20 out of 25 law firms surveyed have made billing process improvement a top priority for 2018. Firms can foster consistency and increase efficiency at all stages of their billing cycle by focusing on a few specific procedures, say Sharon Quaintance and Christine Indiano at HBR Consulting.

  • 10 Tips For Effective Practice Before The 5th Circ.

    Justin Woodard

    The Fifth Circuit is among the busiest federal circuit courts in the country. What can you do to increase your chances of reaching oral argument? And if given the opportunity, how can you present a persuasive argument? Former Fifth Circuit clerk Justin Woodard, an associate at Jones Walker LLP, shares some advice.